VJHemOnc is committed to improving our service to you

BSH 2019 | Follow-up of the ALLR3 trial: pediatric late bone marrow relapse & lessons learned

VJHemOnc is committed to improving our service to you

Vaskar Saha

The ALLR3 trial (NCT00967057) was an open-label, randomized clinical trial that investigated the outcomes of pediatric B-cell precursor acute lymphoblastic leukaemia (ALL) who had late bone marrow relapses and were treated with combination chemotherapy. Here, Vaskar Saha, MBBS, DCH, MD, FRCP, FRCPath, PhD, University of Manchester, Manchester, UK, discusses the follow-up on the trial. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter